PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect

The management of neovascular age‐related macular degeneration: A systematic literature review of patient‐reported outcomes, patient mental health and caregiver burden - Gale - 2023 - Acta Ophthalmologica - Wiley Online Library

PDF) Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study

PDF) Rate of vision loss in neovascular age-related macular degeneration explored

Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study - ScienceDirect

High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration

End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration - ScienceDirect

PDF) Ranibizumab for the treatment of wet AMD: A summary of real-world studies

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model